Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 104

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 104
---
 referred to in this Circular and Proxy Statement have been prepared in accordance with
U.S. GAAP. Shareholders who are resident in Canada should be aware that U.S. GAAP is different from International Financial Reporting Standards generally applicable to companies incorporated in Canada.

NOTICES TO SHAREHOLDERS OUTSIDE OF CANADA

The Company is a corporation incorporated under the Laws of Québec, Canada. The solicitation of proxies and the transactions
contemplated are being carried out in accordance with the Laws of the Province of Québec and the federal Laws of Canada applicable therein. The Company has prepared this Circular and Proxy Statement in accordance with the disclosure
requirements of Canada and of the United States.

Shareholders who are not residents of Canada should be aware that the disposition of
Common Shares pursuant to the Arrangement may have tax consequences both in Canada and in the jurisdiction in which they are resident (including the United States) which may not be described fully herein. The tax treatment of Shareholders pursuant
to the Arrangement is dependent on their individual circumstances and the tax jurisdiction applicable to such Shareholders. It is recommended that Shareholders consult their tax advisors in this regard.

62

THE SPECIAL MEETING

Date, Time and Place

This Circular and
Proxy Statement is being furnished to our Shareholders as part of the solicitation of proxies by the Board for use at the Special Meeting to be held at 10:00 a.m. (Montreal time) on January 16, 2026. The Special Meeting will be hosted via live
webcast only. Any shareholder can attend the virtual Special Meeting live online by registering at www.proxydocs.com/RPTX prior to the deadline of 10:00 a.m. (Montreal time) on January 16, 2026. Upon completing your registration, you will
receive further instructions via email, including your unique links that will allow you access to the Special Meeting and will permit you to submit questions.

Proposals to be Considered at the Special Meeting

At the Special Meeting, our Shareholders will be asked to consider and, if thought advisable, to pass, with or without variation, (i) the
Arrangement Resolution, the full text of which is set forth in Annex D to this Circular and Proxy Statement, approving the Arrangement under Chapter XVI – Division II of the QBCA involving the Company and the Purchaser, pursuant to which,
among other things, the Purchaser will acquire all of the issued and outstanding Common Shares of the Company and the Shareholders will